Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 06'th Aug 2025
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1
Syndax Pharmaceuticals: The Story Brightens
12:59pm, Tuesday, 05'th Aug 2025
Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are dr
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript
11:52pm, Monday, 04'th Aug 2025
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Met
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
06:15pm, Monday, 04'th Aug 2025
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.8 per share a year ago.
Syndax (SNDX) Q2 Revenue Jumps 986%
05:47pm, Monday, 04'th Aug 2025
Syndax (SNDX) Q2 Revenue Jumps 986%
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 04'th Aug 2025
– $28.6 million of Revuforj ® (revumenib) net revenue, representing 43% growth over 1Q25 –
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
01:00pm, Tuesday, 29'th Jul 2025
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
10:56am, Tuesday, 29'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positi
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
07:00am, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
05:18am, Tuesday, 08'th Jul 2025
Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its comm
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 02'nd Jul 2025
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1,
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
04:01pm, Tuesday, 24'th Jun 2025
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA's RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
07:00am, Thursday, 12'th Jun 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 05'th Jun 2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1,
